SR-3306
Based on 1 publication(s) in Google Scholar
SR-3306 is a brain-penetrant and selective pan-JNK (JNK1/2/3) inhibitor. SR-3306 is a neuroprotective agent that can be used for the study of Parkinson's disease, ischemia/reperfusion (I/R) injury and obesity.
연구목적의 판매만을 진행합니다. 환자를 대상으로 한 판매는 하지 않습니다.
- Purity: 98.01%
- CAS No.: 1128096-91-2
- 화학식: C28H26N8O
- 분자량:490.56
-
보관:Powder -20°C, 3 years , 4°C, 2 years ; In solvent -80°C, 2 years , -20°C, 1 year
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Biological Activity
-
Chemical Information
-
용액&용해도
- Protocol
- 순도&문서
- References
-
Help & FAQs
Publications Citing Use of MedChemExpress (MCE) SR-3306
More
Biological Activity
|
JNK |
|
Cell Line
|
Type | Value | Description | References |
|---|---|---|---|---|
| INS1 | IC50 |
0.216 μM
Compound: 16
|
Inhibition of JNK3-mediated c-jun phosphorylation in rat INS1 cells
Inhibition of JNK3-mediated c-jun phosphorylation in rat INS1 cells
|
[PMID: 25415535] |
The effect of SR-3306 or Tat-Sab on cell viability in response to oxidative stress is measured by an MTT assay. H9c2 cells treated with 100 μM H2O2/FeSO4 are ~40% viable, whereas the addition of 500 nM SR-3306 or 500 nM SR3562 to cells treated with 100 μM H2O2/FeSO4 increases viability to ~90%, and the addition of 10 μM Tat-Sab peptide to cells treated with 100 μM H2O2/FeSO4 increases viability to ~70% compared with 98% viability in untreated cells. Similar results are found for primary human cardiomyocytes [2].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
Chemical Information
-
CAS No. 1128096-91-2
-
Appearance Solid
-
분자량 490.56
-
화학식 C28H26N8O
-
Color Off-white to light yellow
-
SMILES
CC(C=C1)=NC=C1C2=NN(C=N2)C3=CC=C(NC4=NC=CC(C5=CC=CC(N6CCOCC6)=C5)=N4)C=C3
-
선적
Room temperature in continental US; may vary elsewhere.
-
보관
Powder -20°C 3 years 4°C 2 years In solvent -80°C 2 years -20°C 1 year
Publications (1)
-
Journal Impact Factor
-
Most Recent
용액&용해도
DMSO : 125 mg/mL (254.81 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
Select the appropriate dissolution method based on your experimental animal and administration route.
- For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
- To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
- The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.
Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline
Solubility: ≥ 2.08 mg/mL (4.24 mM); Clear solution
This protocol yields a clear solution of ≥ 2.08 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (20.8 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.
Preparation of Saline: Dissolve 0.9 g sodium chloride in ddH₂O and dilute to 100 mL to obtain a clear Saline solution.
Please enter the basic information of animal experiments:
-
-
-
-
Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.
Please enter your animal formula composition:
-
%DMSO +
Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
-
%+
-
+%Tween-80 + +
-
%Saline +
The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).
Working solution concentration: 0.22 mg/mL
Method for preparing stock solution: mg drug dissolved in μL DMSO. Stock solution concentration: mg/mL.
1. Take μL DMSO stock solution;
2. Add μL .
μL , mix evenly;
3. Then add μL Tween 80, mix evenly;
4. Then add μL
Please ensure that the stock solution in the first step is dissolved to a clear state, and add co-solvents in sequence. You can use ultrasonic heating (ultrasonic cleaner, recommended frequency 20-40 kHz), vortexing, etc. to assist dissolution.
Protocol
H9c2 cells and primary human cardiomyocytes are grown under normal cell culture conditions (37 °C and 5% CO2) in DMEM supplemented with 10% fetal bovine serum and penicillin/streptomycin. To assure that the cells are actively growing, only cells at ~80% confluency and between passages 5 and 15 are used in our experiments. H9c2 cells and primary human cardiomyocytes are exposed to 500 nM SR-3306, 500 nM SR-3562, 0.01% DMSO vehicle control, 10 μM Tat-SabKIM1, and 10 μM Tat-scramble for 30 min prior to the addition of stress. To induce oxidative stress and mitochondrial dysfunction in H9c2 cells and primary human cardiomyocytes, 100 μM hydrogen peroxide (H2O2)/FeSO4 or 100 μM hydrogen peroxide (H2O2)/FeSO4 is added directly to the media of the cells. The cells are exposed to H2O2/FeSO4 for the times indicated in the experiments[2].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
Rats[1]
Four Sprague-Dawley rats are used. SR-3306 is dosed at 2.5 or 10 mg/kg in subcutaneous minipumps at a rate of 5 μL/h, and after 24 h on days 1, 2, 3, 4, 6, 7, 8, 9, 10, 13, and 14 blood, and day 14 brain are collected. Plasma is generated, and the samples are frozen at -80 °C. The plasma and brain are mixed with Acetonitrile (1:5 v/v or 1:5 w/v, respectively). The brain sample is sonicated with a probe tip sonicator to break up the tissue, and samples are analyzed for compound levels by LC-MS/MS. Plasma compound levels are determined against standards made in plasma and brain levels against standards made in blank brain matrix[1].
Mice[3]
Male, lean or DIO C57BL/6 mice are used. The mice are trained to scheduled, daily, 2-hour water access during the light for 2 weeks. On the first day of the conditioned taste aversion (CTA) test, the trained mice are given a novel 0.15% saccharin solution to drink for the first 50 minutes, and are then given an i.p. injection of SR-3306 (30 mg/kg or 60 mg/kg) or the vehicle. The injected mice are then provided water for the remaining 70 min. The next day, the mice are allowed to choose between water and 0.15% saccharin for 50 min. Fluid consumption is calculated[3].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
순도&문서
-
Data Sheet (278 KB)
-
SDS (254 KB)
- English - EN (254 KB)
- Français - FR (254 KB)
- Deutsch - DE (254 KB)
- Norwegian - NO (254 KB)
- Español - ES (254 KB)
- Swedish - SV (254 KB)
- Italian - IT (254 KB)
- Korean - KR (254 KB)
- Portuguese - PT (254 KB)
-
Handling Instructions (2659 KB)
References
[1]. Crocker CE, et al. JNK Inhibition Protects Dopamine Neurons and Provides Behavioral Improvement in a Rat 6-hydroxydopamine Model of Parkinson's Disease. ACS Chem Neurosci. 2011 Apr 20;2(4):207-212. [Content Brief]
[2]. Gao S, et al. Pharmacological Inhibition of c-Jun N-terminal Kinase Reduces Food Intake and Sensitizes Leptin's Anorectic Signaling Actions. Sci Rep. 2017 Feb 6;7:41795. [Content Brief]
[3]. Chambers JW, et al. Inhibition of JNK mitochondrial localization and signaling is protective against ischemia/reperfusion injury in rats. J Biol Chem. 2013 Feb 8;288(6):4000-11. [Content Brief]
Complete Stock Solution Preparation Table
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.
| Optional Solvent | Concentration Solvent Mass | 1 mg | 5 mg | 10 mg | 25 mg |
|---|---|---|---|---|---|
| DMSO | 1 mM | 2.0385 mL | 10.1924 mL | 20.3849 mL | 50.9622 mL |
| 5 mM | 0.4077 mL | 2.0385 mL | 4.0770 mL | 10.1924 mL | |
| 10 mM | 0.2038 mL | 1.0192 mL | 2.0385 mL | 5.0962 mL | |
| 15 mM | 0.1359 mL | 0.6795 mL | 1.3590 mL | 3.3975 mL | |
| 20 mM | 0.1019 mL | 0.5096 mL | 1.0192 mL | 2.5481 mL | |
| 25 mM | 0.0815 mL | 0.4077 mL | 0.8154 mL | 2.0385 mL | |
| 30 mM | 0.0679 mL | 0.3397 mL | 0.6795 mL | 1.6987 mL | |
| 40 mM | 0.0510 mL | 0.2548 mL | 0.5096 mL | 1.2741 mL | |
| 50 mM | 0.0408 mL | 0.2038 mL | 0.4077 mL | 1.0192 mL | |
| 60 mM | 0.0340 mL | 0.1699 mL | 0.3397 mL | 0.8494 mL | |
| 80 mM | 0.0255 mL | 0.1274 mL | 0.2548 mL | 0.6370 mL | |
| 100 mM | 0.0204 mL | 0.1019 mL | 0.2038 mL | 0.5096 mL |
SR-3306 Related Classifications
HY-12829 Related Classifications
Powered by Bioz